SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
4
17:05-17:20 CAR-T cells Stephen Schuster (Philadelphia)
17:20-17:35 Allo-transplant Peter Dreger (Heidelberg)
17:35-18:05 General discussion
SESSION VII – Efficacy through safety
Chairs: Barbara Eichhorst (Cologne), Javid Moslehi (Nashville)
18:05-18:10 Introduction Barbara Eichhorst (Cologne)
18:10-18:25 Cardiologist Javid Moslehi (Nashville)
18:25-18:40 Dermatologist Nicole LeBoeuf (Boston)
18:40-18:55 Infectious diseases Michele Bartoletti (Bologna)
18:55-19:10 Gastroenterology Stefano Fagiuoli (Bergamo)
19:10-19:40 General discussion
Thursday, November 19, 2020
12:00-13:00 Simultaneous Lunchtime Meet the Expert sessions
1. Treatment of relapsed CLL Paolo Ghia (Milan)/Barbara Eichhorst (Cologne)
2. Management of novel drugs - side effects Carol Moreno (Barcelona)/Davide Rossi (Bellinzona)
3. MRD assessment Andrew Rawstron (Leeds)/Arnon Kater (Amsterdam)
SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)
13:00-13:05 Introduction Davide Rossi (Bellinzona)
John Seymour (Melbourne)
13:05-13:20 Clonal evolution Davide Rossi (Bellinzona)
13:20-13:35 PI3K Jennifer Brown (Boston)
13:35-13:50 Venetoclax John Seymour (Melbourne)
SHORT ORAL COMMUNICATIONS
13:50-13:57 Aid-mediated mechanisms of resistance to BCR
inhibitors in Chronic Lymphocytic Leukemia (CLL) Chiara Pighi (Turin)
13:57-14:04 NOTCH2 contributes to venetoclax resistance
in Chronic Lymphocytic Leukemia Stefania Fiorcari (Modena)
14:04-14:35 General discussion
14:35-14:45 Coffee break